Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Alirocumab in Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY JAPAN
- Sponsors Sanofi
- 05 Jul 2016 Results published in Regeneron media release.
- 05 Jul 2016 According to Regeneron media release, the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.
- 23 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.